Xentria — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Xentria is a private, pre-revenue biotech company operating as a therapeutics developer and partnership facilitator. Its core business model involves forming collaborative partnerships to advance challenging drug candidates, with its lead asset, XTMAB-16, an anti-TNF monoclonal antibody, currently in Phase 2 development for pulmonary sarcoidosis. The company emphasizes adaptive development strategies, deep expertise in biologics, and a values-driven partnership approach to de-risk and accelerate programs for its collaborators.

SarcoidosisImmunologyInflammation

Technology Platform

Integrated development expertise and partnership playbook for challenging biologics and monoclonal antibodies, emphasizing adaptive strategies and deep operational know-how.

Opportunities

The primary opportunity is addressing the high unmet need in pulmonary sarcoidosis with a targeted anti-TNF therapy, potentially capturing a niche orphan drug market.

Secondly, the growing demand for expert-guided development partners in the complex biologics space presents a scalable business model through co-development partnerships and licensing.

Risk Factors

Key risks include clinical failure of the lead asset XTMAB-16, which is central to the company's valuation.

As a pre-revenue private company, it also faces significant funding and execution risks, alongside competition for partnership opportunities and intellectual property.

Competitive Landscape

In sarcoidosis, XTMAB-16 competes with off-label use of existing anti-TNF drugs (e.g., infliximab) and other immunosuppressants. As a development partner, Xentria competes with a broad range of entities, from full-service CROs to other biotech venture studios, all vying to in-license or co-develop promising early-stage science.

More companies in Biologics / Biosimilars →More companies in United States →